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ABSTRACT
Background Inactivating germline mutations in the
tumour suppressor gene BRCA1 are associated with a
signiﬁcantly increased risk of developing breast and
ovarian cancer. A large number (>1500) of unique
BRCA1 variants have been identiﬁed in the population
and can be classiﬁed as pathogenic, non-pathogenic or
as variants of unknown signiﬁcance (VUS). Many VUS
are rare missense variants leading to single amino acid
changes. Their impact on protein function cannot be
directly inferred from sequence information, precluding
assessment of their pathogenicity. Thus, functional
assays are critical to assess the impact of these VUS on
protein activity. BRCA1 is a multifunctional protein and
different assays have been used to assess the impact of
variants on different biochemical activities and biological
processes.
Methods and results To facilitate VUS analysis, we
have developed a visualisation resource that compiles
and displays functional data on all documented BRCA1
missense variants. BRCA1 Circos is a web-based
visualisation tool based on the freely available Circos
software package. The BRCA1 Circos web tool (http://
research.nhgri.nih.gov/bic/circos/) aggregates data from
all published BRCA1 missense variants for functional
studies, harmonises their results and presents various
functionalities to search and interpret individual-level
functional information for each BRCA1 missense variant.
Conclusions This research visualisation tool will serve
as a quick one-stop publically available reference for all
the BRCA1 missense variants that have been functionally
assessed. It will facilitate meta-analysis of functional
data and improve assessment of pathogenicity of VUS.
INTRODUCTION
Breast cancer is the most common cancer in
women and approximately 5%–10% of breast
cancer cases are hereditary, where a germline muta-
tion is present within a known cancer susceptibility
gene.1 Individuals with inherited inactivating muta-
tions in BRCA1 have an increased risk of develop-
ing breast and ovarian cancers.2–4 A recent
prospective study of mutation carriers estimates the
cumulative risk of breast cancer to be 60% (95%
CI 44% to 75%) and of ovarian cancer to be 59%
(95% CI 43% to 76%) by the age of 70 years.5
Inherited mutation in BRCA1 accounts for 40%–
45% of all hereditary breast cancer cases but for
around 80% of cases in families with multiple cases
of breast and ovarian cancers.6 Thus, women with
a strong family history are referred to genetic
testing.
BRCA1 genetic test is based on direct sequencing of
coding exons7 and can have the following outcomes:
no sequence alteration, pathogenic variant, non-
pathogenic variant or variants of unknown signiﬁcance
(VUS).8 Despite early evidence to the contrary, it
seems that individuals from BRCA mutation-positive
families with no sequence alteration or with non-
pathogenic variants are not at increased risk for breast
and ovarian cancer.9–12 Individuals testing positive for
a pathogenic variant have a well-established elevated
risk of developing breast and ovarian cancers.5
However, for those that carry a VUS, test results
cannot be used for risk assessment. Most of these VUS
are alterations in intronic and regulatory regions or
in-frame deletions/insertions and missense variants
whose impact on function cannot be inferred from
the sequence alone.13
Currently, a multifactorial statistical model classi-
ﬁes BRCA variants where each variant is assigned a
prior probability of being pathogenic.14–17 This
model uses data from segregation analysis,
co-occurrence, family history and tumour path-
ology and can be expanded to take into consider-
ation other sources of data. To align variant
classiﬁcation to speciﬁc medical recommendations,
the International Agency for Research on Cancer
(IARC) Unclassiﬁed Genetic Variants Working
Group deﬁned a ﬁve-class system with speciﬁc
probability thresholds.18 Systematic use of this
model has led to the classiﬁcation of a large
number of previously unclassiﬁed variants.16 19
However, despite a wealth of information from
functional assays, these data have not yet been
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incorporated into the multifactorial model. Recently, a computa-
tional approach to infer disease relevance from functional data,
called VarCall, was developed.20 This latest development allows
the systematic integration of functional data into the multifac-
torial model. To facilitate this analysis, we aggregated all data on
functional assays for BRCA1 missense variants into one
easy-to-use lookup tool to effectively determine the functional
signiﬁcance of the documented VUS.
We call this web tool ‘BRCA1 Circos’ and it currently repre-
sents ∼700 documented missense variants (Breast Cancer
Information Core (BIC), http://research.nhgri.nih.gov/bic/).
Circos plots are visualisation tools widely used in the current lit-
erature to represent multidimensional genomic data21 that were
adapted by us to display the BRCA1 missense variants. Besides
the visualisation resource, we have developed a single compre-
hensive database that incorporates all the present information
on BRCA1 missense variants. We used PERL-based Circos
modules to generate the BRCA1 Circos images and developed a
webpage for the Circos to be used as an interactive tool along
with a searchable database of all the variants (the webpage can
be viewed at http://research.nhgri.nih.gov/bic/circos/).
METHODS AND RESULTS
Literature curation
We annotated all the missense variants that had been reported
in (a) the literature or (b) the National Heart, Lung, and Blood
Institute (NHLBI) Exome Sequencing Project (ESP6500SI-V2
release; http://evs.gs.washington.edu/EVS/) or (c) the BIC data-
base totalling 698 variants. We performed an extensive literature
search for all functional assays. If the variants were present in
the BIC, we have indicated the frequency of the variant in
Circos. In addition to the traditional search tools and databases
such as the National Center for Biotechnology Information’s
PubMed and Google Scholars, we also used publically available
databases such as Align-GVGD (http://brca.iarc.fr/PRIORS/
BRCA1/index.php) and the BRCA1 variant literature database
(http://chromium.liacs.nl/LOVD2/cancer/home.php) to docu-
ment the information available on missense variants in these
databases. The information from these sources was used to
develop a database of these variants and, when available, the
impact on BRCA1 function as indicated in the original source.
Online supplementary table S1 contains the complete BRCA1
Circos database. Updated versions will be available for down-
load on the BRCA1 Circos webpage.
Harmonising scores
Regardless of whether the data we obtained from the articles
deﬁned the results categorically or quantitatively, we have fol-
lowed a controlled vocabulary16 to deﬁne functional impact or
no functional impact as mentioned by the authors in the
respective papers. As a rule, we respected the authors’ classiﬁca-
tion/score of individual variants. For example, in a quantitative
test, we followed the authors’ cut-off to determine which
variant had a functional impact and which did not. In some
cases, we might disagree with the ﬁnal classiﬁcation by the
authors; however, without access to the raw data for each indi-
vidual article to allow for reanalysis and without the beneﬁt of
the authors’ expertise in the speciﬁc assays, we have decided to
consistently follow the authors’ determination.
To harmonise scores across all articles, we use controlled
vocabulary previously described.8 16 We classiﬁed variants as
having a ‘functional impact’ or ‘no functional impact’ and inter-
mediate phenotypes with ‘mild functional impact’ or ‘intermedi-
ate functional impact’. Although many papers report a
categorical scoring system (eg, impact vs no impact), others
report a continuous scoring system (eg, as percentage of wild-
type activity) with a deﬁned cut-off value. However, most arti-
cles with continuous data did not have readily accessible raw
data, but rather ﬁgures with histograms that are not amenable to
data extraction and reanalysis. Thus, we decided to use a cat-
egorical (and not quantitative) scoring system for consistency.
Functional impact has been annotated as follows: N, no func-
tional impact; F, functional impact; I, intermediate functional
impact; M, mild functional impact and U, undetermined func-
tional impact on the BRCA1 protein. The ‘intermediate’ and
‘mild functional impact categories’ were created to accommo-
date cases where intermediate values were reported. For
example, in the study by Morris et al,22 BRCA1 Ubiquitin ligase
activity, binding to E2 and BARD1 binding was tested. The
phenotype for each of these functional studies was assigned as
(+++), (++), (+), (−) or (−/+). In this case, (+++) was
deﬁned as ‘no functional impact’, (++) as ‘mild functional
impact’, (+) as ‘intermediate functional impact’, (−) as ‘func-
tional impact’ and (−/+) as undetermined. As described above,
we were always guided by the authors’ interpretation.
It is important to note that functional assays or predictions
from protein sequences and structures can only assess a variant’s
impact on the protein function and not on pathogenicity, a clin-
ical phenotype. Although there is a strong correlation between
defects in protein function and pathogenicity, it is conceivable
that not all variants that abrogate a certain function will lead to
increased risk. The particular function being assayed may be
unrelated to the protein tumour suppressor function.
Conversely, a variant with no detectable impact on a speciﬁc
function may have dramatic effect on a critical function of
BRCA1 that is not the one being assessed.
Circos plot
Circos (http://circos.ca) is a freely available web resource primar-
ily used to represent genomic data.21 Circos provides
PERL-based modules that can be used as the basis to develop
circular visualisation of data. We used these modules to install
Circos and wrote our own script to represent the data present in
our BRCA1 missense variant database. In Circos, each concen-
tric ring is called a ‘track’.
Figure 1 shows all the exons of the BRCA1 gene in the outer-
most track (track 1). Tracks 2 and 3 represent the frequency of
the variant in the BIC database and the IARC class, respectively.
Tracks 4 and 5 depict results from the VarCall computational
model, with track 4 representing the likelihood of being patho-
genic and track 5 showing the associated Bayes’ factor. Track 6
indicates whether the variant is present in the NHLBI Exome
Sequencing Project.23 A brief description for each track can be
seen in table 1 and detailed descriptions and the key to inter-
preting them can be found in the online supplementary material 1
(http://research.nhgri.nih.gov/bic/circos/trackdescriptions/). Missense
variants are shown in tracks 7–9 (reference amino acid: track 7,
codon: track 8, variant amino acid: track 9). The remaining
tracks show the functional impact on the variant as assessed by
different functional assays (tracks 11–53). The functional assess-
ment by each assay/prediction algorithm is colour coded as ‘red’
(functional impact), ‘blue’ (no functional impact), ‘yellow’
(mild/intermediate functional impact) or ‘white’ (no data
available).
The script generates an image ﬁle that was used as the basis
for the webpage. We generated two Circos ﬁgures: one with all
variants in all coding exons (ﬁgure 2) and one removing data
from exon 11 of BRCA1 (ﬁgure 1). This was done because a
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large number of missense variants in exon 11 have been identi-
ﬁed, but the functional data on these variants are sparse.
Therefore, to better visualise the functional data for the other
data-rich exons, we scaled the Circos plot to ﬁve times the
radial size as compared with the ﬁgure (ﬁgure 2) where all
exons are to scale.
Interpreting BRCA1 Circos
The BRCA1 Circos plot should be read radially with track 1
being the outermost and track 53 being the innermost track.
Each track is annotated by a track number and the correspond-
ing data source (table 1). The data in each track are colour
coded, and mouse-over on any data point on the ﬁgure on the
website will allow the track number, track name and variant
information to be displayed. As an example, we look at two var-
iants: M1775K and M1775R (ﬁgure 3). The ﬁrst track shows
the exon; the variants lie in exon 21. Track 2 shows the BIC
entries for each variant as a histogram (numerical values can be
found in the functional database or can be seen using the
mouse-over function on the website ﬁgure). In this case, there
are no entries for M1775K but 31 entries in BIC for M1775R.
Track 3 shows the IARC classiﬁcation18 for each variant and
both variants are IARC class 5 represented as a red dot. Track 4
shows the computational classiﬁcation of transcriptional assay
data. The classiﬁcation is performed based on the posterior
probability that variant is protein damaging; both these variants
have a value of 1, which is represented as a histogram. Track 5
represents the Bayes’ factor and is calculated based on the tran-
scriptional assay data; this is red for both the variants, indicating
high probability of these variants being pathogenic.20 Track 6
indicates whether the variants were found in the ESP Exome
Viewer. Both variants are indicated as white because they were
not found in the ESP Exome viewer. Tracks 7–9 show the
variant M being the reference amino acid, 1775 being the
amino acid position and R and K being the variant amino acids,
respectively. Tracks 11–53 show the functional impact of the
variants using various functional assays and M1775K has lesser
data than M1775R as shown by more white data points for
M1775K. The majority of the functional assays show M1775R
as having a functional impact on the protein. All the colour-
coding information is shown in the database and in the track
descriptions on the website for a consolidated viewing of all the
information described here.
Functional overlap
One of the goals of the BRCA1 Circos is to help in the
meta-analysis of results from individual variants. For example, a
variant ‘A’ that was tested multiple times and scored as of ‘no
functional impact’ in every assay is considered to have stronger
evidence against functional impact than a variant ‘B’ with only
one assay reported in which it scored as no functional impact.
But if all the assays performed for ‘A’ are functionally redundant
(they assay the exact same function) and were performed in
similar conditions, then the evidence against functional impact
for ‘A’ is not stronger than the evidence for ‘B’.
Data in tracks 11–53 represent results from several functional
assays. Some tracks will represent data from the exact same
assay reported in two or more separate papers. Others represent
the same assays with differences in experimental conditions or
design (eg, the transcriptional assay can be done in different cell
types using the same constructs or in the same cell type but
using constructs that span a different region of the protein).
Finally, others can represent completely different experimental
set up and assay a different function (eg, transcriptional activity
in mammalian cells vs recombination in yeast). Thus, the user is
cautioned to be aware of the functional overlap between assays
when interpreting BRCA1 Circos data.
Website development
Using the Circos program, we generated html image maps that
represent the co-ordinates of every data point on the BRCA1
Figure 1 BRCA1 Circos excluding exon 11. (A) BRCA1 Circos with no data on display for exon 11 to facilitate data visualisation for the remaining
exons (see ﬁgure 2 for BRCA1 Circos including exon 11 data). All documented BRCA1 missense variants are represented in the Circos plot that
contains 53 concentric tracks (left panel). (B) Magniﬁed view of the region depicted in the inset (dashed lines) from (A). Refer to table 1 for detailed
descriptions of each track. BRCA1 Circos can be accessed via the website http://research.nhgri.nih.gov/bic/circos/ with mouse-over and search
functionalities.
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Circos image. The BRCA1 Circos website (http://research.nhgri.
nih.gov/bic/circos/) also displays a searchable database with
information on the functional assays and functional prediction
algorithms for BRCA1 variants. The functionalities of the
website are
▸ mouse-over ‘magnifying glass’ to zoom into any region of
the Circos plot to visualise the data in that region;
▸ mouse-over on every data point on the tracks shows a label
with ‘track number, variant (amino acid change), track name
and base change’;
▸ track descriptions and key to interpret the functional data on
every track;
▸ all tracks hyperlinked to the original article where the data
were extracted from;
▸ double-clicking any part of the ﬁgure zooms into that region
and allows the user to pan through the image;
▸ every data point in the Circos ﬁgure is hyperlinked to the
information in the BRCA1 Missense variants functional data-
base (http://research.nhgri.nih.gov/bic/circos/allvariants/).
All codes to develop the BRCA1 Circos and raw ﬁles are
available on request. In the BRCA1 Circos, each track represents
one set of functional assays or prediction algorithms that indi-
cate the functional classiﬁcation of a speciﬁc BRCA1 missense
variant. Two papers reporting the same assay would be dis-
played in two separate tracks. Two separate assays reported in
the same paper would also be displayed as two separate tracks.
The current version of BRCA1 Circos depicts a speciﬁc func-
tional assay per track. As more assays are published, the BRCA1
Circos can be updated by increasing the radius of a Circos plot
which allows for more tracks to be incorporated; however, this
may become unwieldy as the tool needs to ﬁt in a standard com-
puter screen. There are several options to solve to address this
problem when it arises: (a) adding multiple BRCA1 Circos plots
is a simple but the least preferable solution because we would
lose the comprehensive view in one image; (b) taking advantage
of our interactive interface (zooming in and mouse-over func-
tions) and hide or show tracks (assays/studies) according to the
user’s choice and, ﬁnally, (c) tracks that have few variants (eg,
<5) would be removed from the plot and the data would be
available on the database but would not be depicted in the
BRCA1 Circos.
DISCUSSION
Mutations that disrupt BRCA1 lead to a substantial increase in
risk of breast and ovarian cancers.2 5 Thus, genetic testing for
BRCA1 is critical to identify individuals at high risk and can be
used to inform clinical decisions. For example, mutation carriers
might consider prophylactic surgery or increased surveillance.
Current testing for BRCA1 is primarily based on sequencing
exons and exon–intron borders,7 but other approaches that
sequence non-coding regions such as introns and 50 and 30
untranslated region are starting to be used.50
Sequence-based methods can identify DNA variations that can
be used to infer the outcome on the protein product. Thus, var-
iants that cause premature or incorrect termination of the
protein can, for the purposes of clinical management, be
inferred to be pathogenic. However, DNA variants whose effect
on the protein cannot be easily inferred from changes in the
genetic code present an enormous clinical challenge.16 These
variants are usually called VUS and their number is bound to
increase with wide spread sequencing of clinical samples. These
Table 1 Track description for BRCA1 Circos
Track
number Description
Track 1 Exon number
Track 2 BIC entries (BIC; August 2012)—http://research.nhgri.nih.gov/
bic/
Track 3 IARC class16
Track 4 Computational classification of transcriptional assay data20
Track 5 Bayes’ factor20
Track 6 Exome viewer—http://evs.gs.washington.edu/EVS/
Track 7 Reference amino acid
Track 8 Codon
Track 9 Variant amino acid
Track 10 Align-GVGD (http://brca.iarc.fr/PRIORS/BRCA1/index.php)
Track 11 BARD binding22
Track 12 E2 binding22
Track 13 Ubiquitin ligase activity22
Track 14 Ubiquitin ligase activity24
Track 15 Bimolecular fluorescence complementation25
Track 16 Protease sensitivity26
Track 17 Phosphopeptide-binding activity26
Track 18 Phosphopeptide-binding specificity26
Track 19 Transcription assay26
Track 20 Transcription assay27
Track 21 Transcription assay17
Track 22 Transcription assay13
Track 23 Transcription assay28
Track 24 Transcription assay29
Track 25 Transcription assay30
Track 26 Transcription assay31
Track 27 Transcription assay32
Track 28 Transcription assay33
Track 29 Transcription assay34
Track 30 Transcription assay35
Track 31 Transcription assay36
Track 32 Transcription assay37
Track 33 Small colony phenotype38
Track 34 Small colony phenotype39
Track 35 Small colony phenotype40
Track 36 Small colony phenotype41
Track 37 Yeast localisation phenotype41
Track 38 ES viability42
Track 39 ES viability43
Track 40 Restoration of radiation resistance44
Track 41 Increase/restoration in radiation resistance24
Track 42 Homology-directed repair45
Track 43 Homology-directed repair46
Track 44 Homology-directed repair43
Track 45 Single-strand annealing46
Track 46 Centrosome number47
Track 47 Yeast intrachromosomal recombination40
Track 48 Yeast interchromosomal recombination40
Track 49 G2/M checkpoint proficiency24
Track 50 Subcellular localisation/formation of foci after IR48
Track 51 Subcellular localisation/cytoplasmic mislocalisation49
Track 52 Cisplatin response43
Track 53 PARP inhibitor sensitivity43
BIC, Breast Cancer Information Core; ES, Embryonic Stem Cell; GVGD, Grantham
Variation-Grantham Deviation; IR, ionizing radiation; IARC, International Agency for
Research on Cancer; PARP, Poly ADP Ribose Polymerase.
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VUS are primarily missense variants that replace one amino acid
for another and variants that may affect splicing of the
transcript.
Due to the relative rarity of individual variants in the popula-
tion, classical approaches such as family studies or case–control
studies are difﬁcult to conduct. Thus, in the past few years,
several methods have been developed to interrogate the
potential functional impact of a certain variant on the func-
tion of BRCA1.8 These methods are not without their caveats
and caution is warranted when interpreting their results
because BRCA1 is a multifunctional protein but it is still
unclear which functions contribute to its tumour-suppressive
actions. Nevertheless, results from functional assay show a
strong correlation with pathogenicity and provide an import-
ant source of information to help in the classiﬁcation of
VUS.26 Recently, a computational model, called VarCall, was
developed to convert results of functional assays into likeli-
hood ratios of pathogenicity, allowing for functional data to
be incorporated into multifactorial models of variant classiﬁ-
cation.20 Thus, we believe that using functional information
will improve and accelerate the classiﬁcation of variants for
BRCA1.
To facilitate the process of analysing functional data, we
developed a database and a visualisation tool that can display all
the available functional data for individual BRCA1 variants.
This tool allows for the direct comparison of results from differ-
ent functional tests and provides a global picture of the func-
tional coverage in BRCA1. It also provides a resource in which
non-specialists can navigate around different functional assays
and weigh information from several sources. There have been
multiple efforts to facilitate systematic integration of all the data
available on these variants such as the BIC (http://research.nhgri.
nih.gov/bic/) and the LOVD BRCA1/2 literature (http://
chromium.liacs.nl/LOVD2/cancer/home.php) database. However,
there is no comprehensive resource to help interpret and visualise
data available on these variants in the current literature along
with the information from multiple databases. We have developed
a novel web-based resource for the interpretation and visualisa-
tion of BRCA1 missense variants.
BRCA1 Circos is the ﬁrst interactive tool that combines data
for all documented BRCA1 missense variants with an
easy-to-interpret visualisation structure. It combines information
from multiple functional assays and databases in one compre-
hensive layout. Besides the detailed information on every
Figure 2 BRCA1 Circos including
exon 11. All documented BRCA1
missense variants are represented in
the Circos plot that contains 53
concentric tracks. Refer to table 1 for
detailed descriptions of each track.
BRCA1 Circos can be accessed via the
website http://research.nhgri.nih.gov/
bic/circos/ with mouse-over and search
functionalities.
Figure 3 Zooming in on an individual variant. A sample section of the BRCA1 Circos representing two missense variants, M1775K and M1775R, is
shown. Each variant should be read radially to get information on all the tracks for the each variant. Refer to table 1 for detailed descriptions of each
track. BIC, Breast Cancer Information Core; GVGD, Grantham Variation-Grantham Deviation; IARC, International Agency for Research on Cancer.
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variant, this tool is also useful to obtain a global view at the
current data available for missense variants of BRCA1 to guide
future efforts on VUS characterisation.
The data in the BRCA1 missense variant database and, conse-
quently, BRCA1 Circos use controlled vocabulary as discussed
by Lindor et al16 classifying the variants as having a ‘functional
impact’, ‘no functional impact’ or ‘mild/intermediate functional
impact’. This makes it easier to consolidate data from multiple
studies regardless of whether the results were quantitative or
qualitative. These data have been colour coded and represented
in an easy-to-use manner with many different features such as
zooming into a particular exon, variant and obtaining informa-
tion on multiple variants at a glance. We also provide the ori-
ginal articles for every track in the Circos and it is advisable to
read the original publications to obtain any experimental data.
Several limitations apply to the data in the BRCA1 Circos. In
particular, because most assays described here have not been
validated extensively nor were conducted with speciﬁc standard
operating procedures in a clinical environment, results should
be taken with caution. In addition, individual-level data could
suffer from clerical errors, swapped samples, mistakes in con-
structs and other problems that are inherent to research.13 As
the gold standard for VUS classiﬁcation14–16 requires that more
than one independent source of data to classify a variant, func-
tional data represented in the BRCA1 Circos should not, at the
present stage, be considered as a single source for the purposes
of clinical decisions. It is expected that as assays are validated
and reported as likelihood ratios (eg, as in VarCall), the func-
tional data will be incorporated in the multifactorial model. For
rare variants for which genetic data may not be available, it is
possible that properly validated assays could be used as a single
source for clinical decisions but this approach needs to be
further assessed in future studies.
In conclusion, we have developed a web-based tool to visualise
complex data on BRCA1 variants using an open-source resource
—Circos.21 This study can be used as a platform for the develop-
ment of a comprehensive functional database for other cancer sus-
ceptibility genes such as BRCA2 and can be used by researchers
and genetic counsellors to better interpret the function of VUS.
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